Leukotriene modifiers in chronic urticaria.
Bensch
G
G
National Jewish Medical & Research Center, Denver, Colorado, USA.
Borish
L
L
D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D002648:Child; D002908:Chronic Disease; D003521:Cyclopropanes; D004341:Drug Evaluation; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007211:Indoles; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D048448:Phenylcarbamates; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy* / Q000453:epidemiology
D000085:Acetates; D003521:Cyclopropanes; D006634:Histamine H1 Antagonists; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D011804:Quinolines; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds; C093875:montelukast; C062735:zafirlukast